Breaking News Instant updates and real-time market news.

DWDP

DowDuPont

$68.33

1.48 (2.21%)

, BG

Bunge

$70.93

-4.82 (-6.36%)

10:34
09/12/17
09/12
10:34
09/12/17
10:34

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. DowDuPont (DWDP) initiated with an Outperform at Macquarie. 2. Bunge (BG) initiated with a Neutral at Baird. 3. Rite Aid (RAD) initiated with a Hold at Loop Capital. 4. Nike (NKE) was initiated with an Outperform at Bernstein, while Under Armour (UA) was initiated with an Underperform. 5. Houlihan Lokey (HLI) initiated with an Overweight at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

DWDP

DowDuPont

$68.33

1.48 (2.21%)

BG

Bunge

$70.93

-4.82 (-6.36%)

RAD

Rite Aid

$2.44

-0.05 (-2.01%)

NKE

Nike

$53.54

0.51 (0.96%)

UA

Under Armour; also tag UAA

$16.03

-0.3072 (-1.88%)

HLI

Houlihan Lokey

$36.18

0.08 (0.22%)

  • 12

    Sep

  • 18

    Sep

  • 19

    Sep

  • 26

    Sep

  • 28

    Sep

  • 03

    Oct

  • 04

    Oct

DWDP DowDuPont
$68.33

1.48 (2.21%)

09/11/17
09/11/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: DowDuPont (DWDP) initiated with a Buy at BofA/Merrill and an Underweight at Barclays. 2. Brookfield Infrastructure (BIP) initiated with an Outperform at BMO Capital. 3. Micron (MU) initiated with an Outperform at FBN Securities. 4. TechnipFMC (FTI) initiated with a Hold at HSBC. 5. Thor Industries (THO) initiated with a Hold at Aegis. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/12/17
BOFA
09/12/17
NO CHANGE
Target $78
BOFA
Buy
DowDuPont added to the US 1 List at BofA/Merrill
BofA/Merrill analyst Steve Byrne added DowDuPont to the US 1 List due to substantial EBITDA growth from synergies and growth initiatives. The analyst sees several catalysts ahead from the release of pro-forma financials in November, clarity on the dividend policy, near-term synergy realization, and the McKinney board review of the spincos. Byrne rates DowDuPont a Buy with a $78 price target.
09/12/17
LEHM
09/12/17
INITIATION
Target $67
LEHM
Underweight
DowDuPont initiated with an Underweight at Barclays
Barclays analyst Duffy Fischer started DowDuPont with an Underweight rating and $67 price target. The analyst says the Street is placing a higher probability of positive outcomes than he is regarding management direction, the spin company structure, the impact of synergies on the bottom line and the Agriculture business.
BG Bunge
$70.93

-4.82 (-6.36%)

06/07/17
FBCO
06/07/17
NO CHANGE
Target $90
FBCO
Outperform
Bunge price target raised to $90 on increased takeover odds at Credit Suisse
Credit Suisse analyst Robert Moskow raised his price target on Bunge to $90 from $80 citing his view of a higher probability that Glencore will acquire it, as he finds it hard to believe that the company would walk away from a compelling offer. He puts a 50% probability on the stock getting to $98 per share in a Glencore takeover and a 50% chance for Bunge to rise to $82 per share if it remains independent and gets more aggressive with its strategy to create value. Moskow keeps an Outperform rating on Bunge shares, which closed yesterday at $79.29.
09/11/17
BARD
09/11/17
INITIATION
Target $77
BARD
Neutral
Bunge initiated with a Neutral at Baird
Baird analyst Benjamin Kallo initiated Bunge with a Neutral and a $77 price target citing global agriculture headwinds in the intermediate term and would look to become more constructive on pullback or an improvement in the agriculture market.
09/12/17
VERF
09/12/17
DOWNGRADE
VERF
Hold
Bunge downgraded to Hold from Buy at Vertical Group
Vertical Group downgraded Bunge to Hold following the acquisition of 70% interest in IOI Loders Croklaan.
09/12/17
09/12/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Bristol-Myers (BMY) downgraded to Neutral from Long-Term Buy at Hilliard Lyons with analyst Kurt Kemper citing share appreciation as shares have approached his previous $65 price target. 2. Bunge (BG) downgraded to Hold from Buy at Vertical Group citing the acquisition of 70% interest in IOI Loders Croklaan. 3. Advance Auto Parts (AAP) downgraded to Sell from Neutral at Citi with analyst Kate McShane saying the company's turnaround seems to be taking longer given the number of issues to fix, and its cost savings are unlikely to impact earnings given its needed investments. 4. Precision Drilling (PDS) downgraded to Neutral from Overweight at JPMorgan. 5. Nucor (NUE) and Steel Dynamics (STLD) were downgraded to Equal Weight from Overweight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
RAD Rite Aid
$2.44

-0.05 (-2.01%)

07/20/17
LEER
07/20/17
NO CHANGE
Target $86
LEER
Outperform
Walgreens, Rite Aid deal still facing 'significant hurdle,' says Leerink
Leerink analyst David Larsen says that even though Walgreens Boots Alliance (WBA) and Rite Aid (RAD) restructured their transaction, he still believes it will be difficult to receive FTC approval. Although the asset purchase agreement may address local market concerns, the FTC will still focus on "national markets" and a declining Rite Aid might actually be another headwind, he argues. Larsen reiterates an Outperform rating and $86 price target on Walgreens' shares.
07/20/17
07/20/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pfizer (PFE) downgraded to Neutral from Outperform at Credit Suisse with analyst Vamil Divan saying he believes the stock's upside drivers are more limited over the next year. 2. Rite Aid (RAD) downgraded to Neutral from Buy at Mizuho. 3. Fairmount Santrol (FMSA) was downgraded to Sell from Neutral at Goldman Sachs and to Neutral from Outperform at Credit Suisse. 4. New Relic (NEWR) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Sanjit Singh saying shares are up 71% year-to-date and valuation captures solid fundamentals but sees fewer catalysts. 5. Smart Sand (SND) downgraded to Neutral from Outperform at Credit Suisse with analyst James Wicklund saying the regional sand volumes capacity is expanding much faster than had been expected. This drives lower pricing and demand for non-Texas mines, he adds. The analyst also lowered his price target on the shares to $8.50 from $20. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/11/17
LOOP
09/11/17
INITIATION
Target $2.5
LOOP
Hold
Rite Aid initiated with a Hold at Loop Capital
Loop Capital analyst Andrew Wolf started Rite Aid (RAD) with a Hold rating and $2.50 price target, stating that he views the company's re-worked store sale to Walgreens (WBA) as a "re-launch of Rite Aid's turnaround efforts" and believes it lacks intermediate term earnings visibility.
08/23/17
UBSW
08/23/17
NO CHANGE
Target $96
UBSW
Buy
Walgreens Boots Alliance should see upside from new Rite Aid deal, says UBS
UBS analyst Michael Cherny said his review of the new Walgreens Boots Alliance (WBA) deal with Rite Aid (RAD) would provide immediate accretion from synergy opportunities if the deal is approved. He believes it can provide meaningful upside to earnings as well as remove the lack of clarity on capital deployment-driven earnings contribution. Thus, he sees the shares as having a positive risk/reward skew. Cherny reiterated his Buy rating and lowered his price target to $96 from $97 on Walgreens shares.
NKE Nike
$53.54

0.51 (0.96%)

08/29/17
ADAM
08/29/17
NO CHANGE
Target $8
ADAM
Hold
Finish Line price target lowered to $8 from $14 at Canaccord
Canaccord analyst Camilo Lyon lowered his price target on Finish Line (FINL) to $8 from $14 after the company preannounced weak Q2 results and lowered guidance for the balance of the year. The analyst said the company is yet another victim of the downturn in the athletic category, which he believes is product driven, starting and ending with Nike (NKE). He said there has been little to no product innovation in more than two years. Once it begins, it could mark a turnaround for the retailers, said Lyon, who maintained his Neutral rating on Finish Line shares.
09/01/17
OPCO
09/01/17
NO CHANGE
Target $68
OPCO
Outperform
lululemon multiple expansion warranted after Q2 results, says Oppenheimer
Oppenheimer analyst Anna Andreeva believes multiple expansion for shares of lululemon (LULU) is warranted following last night's Q2 results. Despite an intensifying promotional backdrop in athletic, lululemon's "powerful brand equity with extremely loyal consumer" posted top-line acceleration, Andreeva tells investors in a post-earnings research note. The retailer's valuation is in line with Nike (NKE) despite "far superior" top-line growth, the analyst contends. She raised her estimates and keeps an Outperform rating on lululemon.
09/12/17
BERN
09/12/17
INITIATION
Target $69
BERN
Outperform
Nike initiated with an Outperform at Bernstein
Bernstein analyst Jamie Merriman started Nike with an Outperform and $69 price target saying it is the best in class athletic apparel and footwear brand and the leader in market share globally. Given the pipeline of innovation, the strength of the R&D platform and the ability to invest in athletes driven by the size of the balance sheet, the analyst believes share gains will continue.
08/29/17
MSCO
08/29/17
NO CHANGE
Target $50
MSCO
Overweight
Foot Locker problems fixable, mostly fashion-related, says Morgan Stanley
Morgan Stanley analyst Jay Sole made his case for keeping an Overweight rating on Foot Locker (FL) in a new note to investors, arguing that the problems that caused the company's "very disappointing" Q2 results were not structural, but "mostly fashion-related" and fixable. He still sees the stock's risk/reward balance skewed to the upside, based on his belief that Foot Locker can defend itself versus Amazon (AMZN), Nike's (NKE) new product pipeline should eventually improve and brands' quicker speed to market "could be a game-changer." However, Sole has lowered his price target on Foot Locker shares to $50 from $65.
UA Under Armour; also tag UAA
$16.03

-0.3072 (-1.88%)

09/12/17
BERN
09/12/17
INITIATION
Target $14
BERN
Underperform
Under Armour initiated with an Underperform at Bernstein
Bernstein analyst Jamie Merriman started Under Armour with an Underperform rating and $14 price target as he believes it is now in "growth purgatory." While growth will remain in the high single digits-low double digits, the analyst does not believe recovering back to over 20% will occur on a sustainable basis.
08/18/17
SBSH
08/18/17
NO CHANGE
Target $81
SBSH
Buy
Foot Locker results and guidance 'greatly disappoints,' says Citi
Citi analyst Kate McShane says Foot Locker's (FL) Q2 results and outlook "greatly disappoints." The company posted its first negative comp since Q4 of 2009, McShane tells investors in a post-earnings research note. Along with Foot Locker, the analyst expects weakness in shares of Nike (NKE) and Finish Line (FINL) as well as Under Armour (UAA, UA) and Dick's Sporting Goods (DKS). McShane currently has a Buy rating on Foot Locker.
08/02/17
08/02/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Under Armour (UA, UAA) downgraded to Neutral from Buy at Citi with analyst Kate McShane citing yesterday's guide-down, the shares look "too expensive for investors to jump into the name nearer-term." 2. Burlington Stores (BURL) downgraded to Neutral from Outperform at Credit Suisse with analyst Christian Buss saying that although the fundamentals of the company remain healthy, he sees limited upside to valuation as the multiples stay elevated despite more moderate industry growth prospects. 3. Big 5 Sporting (BGFV) downgraded to Hold from Buy at Deutsche Bank with analyst Mike Baker saying he expected Big Five's sales gains following The Sports Authority liquidation would decelerate at some point, but he notes that "trends fell off faster and to a greater extent than we suspected." 4. Ultimate Software (ULTI) downgraded to Hold from Buy at Deutsche Bank with analyst Nandan Amladi calling the second quarter results "mixed" and prefers to move to the sidelines until growth returns to the mid-20s target and leverage returns to the model. 5. ResMed (RMD) was downgraded to Neutral from Buy at BofA/Merrill and to Neutral from Outperform at Credit Suisse. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/02/17
SBSH
08/02/17
DOWNGRADE
Target $21
SBSH
Neutral
Under Armour downgraded to Neutral from Buy at Citi
Citi analyst Kate McShane downgraded Under Armour (UAA) and lowered her price target for the shares to $21 from $25. Following yesterday's guide-down, the shares look "too expensive for investors to jump into the name nearer-term," McShane tells investors. She expects the stock will continue trading in a tight range until the end of the year. Under Armour closed yesterday down 9%, or $1.72, to $18.30.
HLI Houlihan Lokey
$36.18

0.08 (0.22%)

09/12/17
JPMS
09/12/17
INITIATION
Target $42
JPMS
Overweight
Houlihan Lokey initiated with an Overweight at JPMorgan
JPMorgan analyst Kenneth Worthington started Houlihan Lokey with an Overweight rating and $42 price target. The company's leadership position in its three businesses segments should drive pricing resiliency and better economics relative to peers, the analyst contends.
05/11/17
05/11/17
DOWNGRADE
Target $38

Neutral
Houlihan Lokey downgraded to Neutral on valuation at BofA/Merrill
As previously reported, BofA/Merrill downgraded Houlihan Lokey to Neutral from Buy and raised its price target to $38 from $36. Analyst Michael Needham downgraded shares citing valuation and slowing restructuring activity.
05/11/17
BOFA
05/11/17
DOWNGRADE
BOFA
Neutral
Houlihan Lokey downgraded to Neutral from Buy at BofA/Merrill
02/02/17
JMPS
02/02/17
NO CHANGE
JMPS
Houlihan Lokey reported 'strong' results, says JMP Securities
JMP Securities analyst Devin Ryan says that Houlihan Lokey reported "strong" results, and he expects the company's earnings to rise "over time." He reiterates a $34 price target and an Outperform rating on the stock.

TODAY'S FREE FLY STORIES

DLTR

Dollar Tree

$112.88

-1.96 (-1.71%)

16:06
01/16/18
01/16
16:06
01/16/18
16:06
Initiation
Dollar Tree initiated  »

Dollar Tree initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BGNE

BeiGene

$102.86

-0.42 (-0.41%)

16:06
01/16/18
01/16
16:06
01/16/18
16:06
Syndicate
BeiGene files to sell $650M in ADSs »

Goldman Sachs & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDHL

RedHill Biopharma

$5.22

0.05 (0.97%)

16:05
01/16/18
01/16
16:05
01/16/18
16:05
Hot Stocks
Breaking Hot Stocks news story on RedHill Biopharma »

683 Capital Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

GNCA

Genocea

$1.08

-0.045 (-4.00%)

16:05
01/16/18
01/16
16:05
01/16/18
16:05
Syndicate
Genocea files to sell common stock, warrants, and convertible preferred stock »

Genocea announced today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$58.13

-1.12 (-1.89%)

16:05
01/16/18
01/16
16:05
01/16/18
16:05
Earnings
CSX reports Q4 EPS 64c, consensus 56c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 01

    Mar

IBKR

Interactive Brokers

$62.45

-0.65 (-1.03%)

16:05
01/16/18
01/16
16:05
01/16/18
16:05
Earnings
Interactive Brokers reports Q4 EPS (2c), consensus 40c »

Excluding the impact of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

DG

Dollar General

$98.50

-0.6 (-0.61%)

16:04
01/16/18
01/16
16:04
01/16/18
16:04
Initiation
Dollar General initiated  »

Dollar General initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMS

Maximus

$71.42

-0.47 (-0.65%)

16:04
01/16/18
01/16
16:04
01/16/18
16:04
Hot Stocks
Maximus appoints Bruce Caswell as CEO after retirement of Richard Montoni »

Maximus announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTGM

HTG Molecular

$3.50

-0.14 (-3.85%)

16:04
01/16/18
01/16
16:04
01/16/18
16:04
Syndicate
HTG Molecular files to sell $10M shares of common stock »

Leerink Partners LLC and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OBLN

Obalon Therapeutics

$7.93

0.03 (0.38%)

16:03
01/16/18
01/16
16:03
01/16/18
16:03
Syndicate
Obalon Therapeutics files to sell $35M on common stock »

UBS Investment Bank,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

NTNX

Nutanix

$36.01

-1.83 (-4.84%)

16:03
01/16/18
01/16
16:03
01/16/18
16:03
Syndicate
Breaking Syndicate news story on Nutanix »

Nutanix files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

UAA

Under Armour; also tag UA

$13.63

-1.49 (-9.85%)

15:55
01/16/18
01/16
15:55
01/16/18
15:55
Options
Under Armour Class A put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:55
01/16/18
01/16
15:55
01/16/18
15:55
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

LVS

Las Vegas Sands

$72.58

1.56 (2.20%)

15:52
01/16/18
01/16
15:52
01/16/18
15:52
Periodicals
Breaking Periodicals news story on Las Vegas Sands »

Las Vegas Sands added as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMST

HomeStreet

$32.35

1 (3.19%)

15:48
01/16/18
01/16
15:48
01/16/18
15:48
Hot Stocks
HomeStreet raises company-wide minimum wage to $15 per hour »

HomeStreet announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

HUM

Humana

$270.41

2.39 (0.89%)

15:45
01/16/18
01/16
15:45
01/16/18
15:45
Options
Humana call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

USB

U.S. Bancorp

$57.46

0.48 (0.84%)

15:45
01/16/18
01/16
15:45
01/16/18
15:45
Hot Stocks
U.S. Bancorp names CEO Andy Cecere chairman of the board »

U.S. Bancorp, parent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

LADR

Ladder Capital

$14.53

0.94 (6.92%)

15:39
01/16/18
01/16
15:39
01/16/18
15:39
Upgrade
Ladder Capital rating change  »

Ladder Capital upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 01

    Feb

ONCE

Spark Therapeutics

$52.66

-1.41 (-2.61%)

15:30
01/16/18
01/16
15:30
01/16/18
15:30
Hot Stocks
Spark Therapeutics treatment of hemophilia A granted FDA orphan status »

Spark Therapeutics'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

PX

Praxair

$161.26

-2.89 (-1.76%)

15:30
01/16/18
01/16
15:30
01/16/18
15:30
Options
$6M option print in Praxair as shares deflate »

$6M option print in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

CGI

Celadon Group

$6.20

-0.4 (-6.06%)

15:26
01/16/18
01/16
15:26
01/16/18
15:26
Periodicals
Celadon Group mentioned cautiously again by Prescience Point 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RGSE

RGS Energy

15:24
01/16/18
01/16
15:24
01/16/18
15:24
Hot Stocks
Iroquois Capital reports 6.3% stake in Real Goods Solar »

This activist stake held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGM

MGM Resorts

$36.09

1.06 (3.03%)

15:20
01/16/18
01/16
15:20
01/16/18
15:20
Options
Notable spread in MGM as shares rally »

Notable spread in MGM as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

15:17
01/16/18
01/16
15:17
01/16/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
01/16/18
01/16
15:16
01/16/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.